Coherus BioSciences Inc (CHRS)

1.895 -0.22 (-10.61%) USD  |  NASDAQ  |  May 10, 16:00
1.91 +0.02 (+0.79%) After-Hours: 18:01
More

Coherus BioSciences Research and Development Expense (Quarterly): 26.37M for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.
Date Value
December 31, 2023 26.37M
September 30, 2023 25.65M
June 30, 2023 23.27M
March 31, 2023 34.15M
December 31, 2022 29.02M
September 30, 2022 45.81M
June 30, 2022 41.61M
March 31, 2022 82.92M
December 31, 2021 50.76M
September 30, 2021 54.08M
June 30, 2021 54.77M
March 31, 2021 203.49M
December 31, 2020 44.63M
September 30, 2020 38.85M
June 30, 2020 26.17M
March 31, 2020 33.11M
December 31, 2019 34.95M
September 30, 2019 21.57M
June 30, 2019 18.88M
March 31, 2019 18.79M
December 31, 2018 26.66M
Date Value
September 30, 2018 31.60M
June 30, 2018 26.52M
March 31, 2018 25.46M
December 31, 2017 31.49M
September 30, 2017 42.63M
June 30, 2017 34.50M
March 31, 2017 53.78M
December 31, 2016 59.01M
September 30, 2016 64.57M
June 30, 2016 65.54M
March 31, 2016 65.31M
December 31, 2015 51.43M
September 30, 2015 68.22M
June 30, 2015 56.94M
March 31, 2015 36.47M
December 31, 2014 26.87M
September 30, 2014 18.50M
June 30, 2014 18.92M
March 31, 2014 13.94M
December 31, 2013 9.222M
September 30, 2013 4.934M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

18.88M
Minimum
Jun 2019
203.49M
Maximum
Mar 2021
46.85M
Average
34.95M
Median
Dec 2019

Research and Development Expense (Quarterly) Benchmarks

AbbVie Inc 1.939B
Inovio Pharmaceuticals Inc 17.25M
Nektar Therapeutics 29.94M
Avid Bioservices Inc --
Stereotaxis Inc 2.212M